cute lymphoblastic leukemia, the most common childhood cancer, is highly responsive to chemotherapy. Among patients receiving contemporary therapy, the overall five-year survival rate is 80 to 86 percent 1,2 and the five-year event-free survival rate is 78 to 83 percent. [3] [4] [5] Each year in the United States, approximately 2000 patients become five-year survivors of childhood acute lymphoblastic leukemia. 6 Although most of these patients are likely to be cured, a substantial proportion will die of leukemic relapse, a second cancer, or some other treatment-related complication during the next five years of followup. 7, 8 Hence, long-term survivors of childhood acute lymphoblastic leukemia are still perceived by many to have an excessive risk of cancer or other catastrophic disease. This perception can lead to the denial of life insurance or health insurance or an offer of restricted or costly coverage.
Adverse events after treatment of acute lymphoblastic leukemia tend to occur within the first decade after diagnosis. 7, 8 We therefore sought to determine the prospects for normal survival among patients attaining at least 10 years of complete remission.
study population and treatment protocols
From 1962 through 1992, 2069 patients with acute lymphoblastic leukemia under 21 years of age were enrolled in 13 consecutive clinical trials (Table 1) [9] [10] [11] [12] [13] at St. Jude Children's Research Hospital in Memphis, Tennessee; 1112 patients survived for 10 years or more after the induction of remission. In this cohort of survivors, 856 who had no leukemic recurrence were considered eligible for the follow-up analysis.
follow-up procedures
After the completion of therapy, all patients were examined at least annually at our center. Patients who had remained in remission for at least 10 years and were 18 years of age or older were subsequently monitored by their local physicians. The status of these patients was ascertained by questionnaires sent annually by the hospital's tumor registrar. The records of patients who died or had a second cancer were reviewed. Histopathological samples of second cancers were reviewed by St. Jude pathologists. For deaths outside the institution, death certificates were routinely requested, and the reported cause was verified by telephone conversations with the local physician, the family, or both. When available, reports of postmortem examinations were also reviewed. At the time of our analysis, only 44 patients (5.1 percent) lacked a documented contact within the previous three years; 599 (70.0 percent) had been contacted within the previous year. The median follow-up for patients attaining at least 10 years of event-free survival was 18.9 years (range, 10.0 to 38.6).
With the approval of the institutional review board, a questionnaire was mailed to all eligible patients who were at least 18 years of age to ascertain health insurance coverage and other socioeconomic characteristics. The results were compared with findings in the general population of the United States in 2000 and 2001. [14] [15] [16] statistical analysis
Survival and event-free survival from the 10th anniversary date of event-free survival (base line) were estimated by the method of Kaplan and Meier, and the associated standard errors were calculated by the method of Peto and Pike. 17 Survival estimates for different groups of patients were compared by a Cox proportional-hazards regression model adjusted for age at the diagnosis of leukemia, sex, race, and treatment era (studies 1 to 10 vs. studies 11 to 13). The duration of event-free survival was measured from base line to the date of the first treatment failure of any kind (relapse, second cancer, or death) or to the date of the last follow-up. Cumulative incidence functions for second cancers, relapses, and deaths during remission were analyzed by Gray's method 18 and with use of a proportional-hazards model adjusted for age and leukocyte count at diagnosis. 19 Standardized mortality ratios (the observed number of deaths divided by the expected number) and their 95 percent confidence intervals were calculated by the method of Breslow and Day. 20 The expected number of deaths was calculated with the Epilog Plus Program 21 by multiplying the number of person-years of follow-up by the corresponding mortality rate in the general population matched for age, sex, race, and calendar year (1973 to 2000) in which our patients achieved their first 10 years of event-free survival. Confidence intervals were calculated by Byar's approximation. 20 The survival curve of the U.S. population was constructed as a linear interpolation of the expected survival for each year from 1973 to 2000. The expected survival in a cal-n engl j med 349;7 www.nejm.org august 14 , 2003 The new england journal of medicine 642 endar year was calculated as 1 minus the expected risk of death in that year, which was defined as the expected number of deaths in that year divided by the total number of patients at risk. The expected number of deaths in a calendar year was calculated by multiplying the number of patients at risk in that year by the average death rate in the U.S. population from 1973 to 2000, after adjustment for age, sex, and race.
The standardized incidence ratio, or the number of observed cases divided by the number of expected cases, for second cancers was calculated on the basis of data from the Surveillance, Epidemiology, and End Results (SEER) program, adjusted for age and sex. Confidence intervals were calculated by Byar's approximation or, in cases with two or fewer observed events, by the exact Poisson distribution.
The summary statistics and national average rates of marriage, employment, and health insurance coverage were stratified according to sex and age categories identical to those of the Medical Expenditure Panel Survey 14 or the Current Population Surveys of the U.S. Census Bureau. 15, 16 Confidence intervals were calculated by exact multinomial statistics. The age-adjusted national average was calculated as the sum of the fraction of participants in each age category multiplied by the sex-specific rate of employment or marital status (Current Population Surveys) or by the insurance rate for that age category (Medical Expenditure Panel Survey). Multiple logistic-regression analysis was used to com-* Irradiation was given together with intrathecal methotrexate.
† Irradiation was given together with intrathecal methotrexate, hydrocortisone, and cytarabine. pare the rates of marriage, employment, and health insurance coverage between the patients who received cranial or craniospinal radiation therapy as part of their initial treatment (irradiated group) and those who did not receive such therapy (nonirradiated group), with adjustment for age and leukocyte count at the diagnosis of acute lymphoblastic leukemia, age at the time of survey, sex, and race. All reported P values are two-sided.
patient characteristics
Of the 856 patients studied, 419 (48.9 percent) were male and 788 (92.1 percent) were white. Their ages ranged from 0.2 to 20 years (median, 4.5) at the time of diagnosis and from 10.3 to 30.2 years (median, 14.6) when they attained 10 years of event-free survival. The median leukocyte count at diagnosis was 8600 per cubic millimeter (range, 800 to 999,000).
Of the 549 cases with successful immunophenotyping, 475 (86.5 percent) were classified as B-lineage acute lymphoblastic leukemia. Hyperdiploid karyotypes (more than 50 chromosomes) were identified in 195 of the 499 cases analyzed (39.1 percent).
adverse events
Fifty-six patients had adverse events after the 10th anniversary date of event-free survival ( Table 2 ). The cumulative incidence ( ± SE) of any adverse event was 5.1 ± 0.9 percent at 10 years after base line (20 years after the induction of remission) and 22.0 ± 3.8 percent at 20 years after base line (30 years after the induction of remission). When basal-cell carcinoma was excluded, these rates were 4.7 ± 0.9 percent and 14.7 ± 2.9 percent, respectively ( Fig. 1) . With three exceptions, the second neoplasms occurred within or adjacent to the field of cranial or craniospinal irradiation. Only one second neoplasm (Hodgkin's disease) was found among the 259 patients in the nonirradiated group. In a proportional-hazards regression model adjusted for age and leukocyte count at diagnosis, the 597 patients in the irradiated group had a significantly higher cumulative risk of second neoplasms than did the 259 patients in the nonirradiated group (P=0.04; estimated cumulative incidence rate at 20 years after base line, 20.9 ± 3.9 percent vs. 0.95 ± 0.9 percent) (Fig. 2) . By comparison with data from the SEER program, we determined that the risk of a second neoplasm was increased only in the irradiated group (Table 3) . The irradiated group also appeared to be at greater risk for any adverse event (P=0.08; estimated cumulative risk rate at 20 years from base line, 23.0 ± 3.8 percent vs. 2.7 ± 1.4 percent) (Fig. 2) . survival At 20 years from base line (30 years from achievement of the first complete remission), the estimated survival rates for the entire group and the irradiated and nonirradiated groups were 95.3 ± 2.2, 95.1 ± 2.3, and 98.3 ± 7.4 percent, respectively, as compared with 99.7 percent for the general U.S. population (Fig. 3) . Twenty-one patients, of whom 18 were in the irradiated group, died at 1.0 to 17.6 results * Five deaths (three from car accidents, one from obstetrical complications, and one from unknown causes) occurred in the irradiated group and three (two from suicide and one from a car accident) in the nonirradiated group. † Two relapses occurred in Study 10 and one each in Study 9 and Study 11. ‡ Other carcinomas included four thyroid carcinomas, two hepatocellular carcinomas, two squamous-cell carcinomas, two parotid-gland carcinomas, and one each of breast cancer, ovarian adenocarcinoma, papillary carcinoma of the bladder, and pancreatic neuroendocrine carcinoma. Of the 694 eligible patients, 584 (84.1 percent) responded to the study questionnaire. Only 44 patients (6.3 percent) declined to participate; current addresses and telephone numbers were not available for the remaining 66 patients. The median age of the respondents was 27 years (range, 18 to 50), and the median time from the diagnosis of leukemia to the date of response to the survey was 20 years (range, 10 to 37). Forty-seven percent of the respondents were men. The marital rate (the proportion of patients currently married) was similar to that in the age-and sex-matched general population, with the exception of women in the irradiated group, whose marital rate (35.2 percent; 95 percent confidence interval, 27.6 to 43.3 percent) was lower than in the corresponding general population (48.8 percent) (Table 4). Most respondents were employed full time (51.7 percent) or part time (7.8 percent); 22.0 percent were students. The rate of full-time employment for nonirradiated patients was similar to that of the age-and sex-matched general population (Table 4). However, in the irradiated group the unemployment rates for both women (35.4 percent; 95 percent confidence interval, 27.0 to 44.1 percent) and men (15.1 percent; 95 percent confidence interval, 9.2 to 22.7 percent) were higher than those in the corresponding general population (5.2 and 5.4 percent, respectively); women in the irradiated group were also less likely to be employed full time.
Health insurance was provided through the employer, spouse, or parent in 59.2 percent of cases; federal or state-supported health plans in 15.1 percent; and self-purchase in 6.9 percent. Only 19.7 percent of the respondents lacked health insurance. A history of leukemia had resulted in the denial of health insurance to 28.4 percent of the respondents, prohibitive premiums for 18.6 percent, and restrictions on health care plans for 7.0 percent. As compared with those with private insurance, respondents with public insurance were more likely to report some difficulty in obtaining health care (13.9 percent vs. 6.6 percent) or not receiving needed care (20.9 percent vs. 4 percent). Not surprisingly, an even greater proportion of uninsured survivors reported difficulties in obtaining health care (19.6 percent) or not receiving needed care (27.7 percent). Although 89.3 percent of the long-term survivors reported using a community physician for their health care needs, only 53.2 percent had seen a physician in the preceding 12 months.
Multiple logistic-regression analysis, adjusted for potentially confounding factors, indicated similar rates of health insurance coverage and marriage for irradiated and nonirradiated patients of the same sex. However, the unemployment rate was higher among female survivors in the irradiated group than in the nonirradiated group (odds ratio, 2.15; 95 percent confidence interval, 1.10 to 4.20).
Among survivors of childhood acute lymphoblastic leukemia who were event-free for 10 years after discussion the induction of remission, the cumulative risk of relapse was only 0.63 ± 0.32 percent at 20 years (30 years after the induction of an initial complete remission). Another research group reported an actuarial risk of relapse of 1 percent at 20 years of follow-up among 1134 survivors who were event-free for 10 years and who had been treated between 1970 and 1984, but the investigators did not determine the incidence of other adverse events in their cohort. 22 The risk of late relapse is likely to be even less in survivors who are event-free for 10 years and who have been treated according to contemporary protocols. 23 Our results suggest a new working definition of cure: 10 or more years of continuous complete remission, a standard that could be used to gauge the effectiveness of current and future treatment plans.
The cumulative risk of second neoplasms in children treated for acute lymphoblastic leukemia is less than 4 percent 15 to 20 years after the diagnosis. 3, 6, [24] [25] [26] [27] Our study showed that the cumulative incidence of second neoplasms in patients who received cranial or craniospinal irradiation rose sharply 20 years after the diagnosis of acute lymphoblastic leukemia, a finding not previously appreciated because of shorter follow-up in other studies. Most of these late-onset second neoplasms were benign tumors or low-grade cancers, and only 12 of 44 patients with second neoplasms died, in contrast to the high mortality rate among patients whose second neoplasms developed within 10 years after the diagnosis of acute lymphoblastic leukemia. 3, [6] [7] [8] [24] [25] [26] [27] [28] [29] Consequently, the long-term survival in the irradiated group in our study was only slightly less than that in sex-and age-matched persons in the general population (Fig. 3) . Survival in the nonirradiated group was virtually identical to that in the general population.
Any assessment of the long-term survival of persons cured of cancer must consider the quality of life. 30 Young adult survivors of childhood cancer have lower marital rates than the general population, [31] [32] [33] [34] [35] [36] and survivors of brain tumors are especially vulnerable. 32, 36 This finding has been attributed to the sequelae of the treatment, including neuroendocrine dysfunction that affects height and body build and neurocognitive deficits that influence social and emotional development. 32 Cranial irradiation is a risk factor for learning deficits in survivors of brain tumors or acute lymphoblastic leukemia, especially in young patients treated with high doses of radiation. 35, 37 Although the doses of cranial radiation delivered to our patients were relatively low (18 to 24 Gy), we found higher unemployment rates and lower marital rates among the women in the irradiated group than in the age-and sex-matched general population, a result consistent with the greater vulnerability of female patients to the adverse effects of cranial irradiation on the central nervous system. [38] [39] [40] These results support current efforts to limit the use of cranial irradiation in initial therapy for acute lymphoblastic leukemia. 3, 41, 42 In two recently published clinical trials, cranial irradiation was omitted altogether, without an undue increase in the rate of central nervous system relapse. 43, 44 Previous investigations of the insurance cover- The new england journal of medicine 646 age of survivors of childhood cancer found clear evidence of discrimination, particularly in employment-related health insurance. 34, 35, [45] [46] [47] [48] [49] Survivors were also more likely than sibling controls to have policies with clauses excluding coverage of preexisting health conditions. 34, 35, 48 More recent studies of older survivors treated according to contemporary protocols indicate improved access to insurance and less economic discrimination, 34, 35 probably because of the public's awareness of the favorable prognosis for most survivors of childhood cancer and because of legislation prohibiting discrimination in employment and promoting insurance portability. [50] [51] [52] Our data indicate that the rate of insurance coverage for long-term survivors of acute lymphoblastic leukemia is at least similar to or, in the case of female survivors, higher than that in the general population. Adult survivors of childhood cancer are at risk for health problems that may adversely affect their quality of life and long-term survival. 7, 8, 53, 54 Because these risks may be exacerbated by the physiologic changes associated with normal aging, lifelong * Basal-cell carcinoma, squamous-cell carcinoma of the skin, and meningioma are excluded; two cases of soft-tissue sarcoma are included. † Meningioma is not included; four patients received 18 Gy of cranial irradiation, and the remaining patient received 24 Gy. ‡ Hepatitis B was diagnosed in one patient, and hepatitis C in the other (therapy for acute lymphoblastic leukemia began in 1964 and 1971, respectively). § Both patients had received teniposide, but neither had an 11q23 rearrangement in the myeloid blasts. medical monitoring is recommended for all survivors of childhood cancer. Although 89 percent of the survivors of acute lymphoblastic leukemia who were discharged from follow-up at our institution reported having a usual place to obtain health care, only 53 percent had had a medical evaluation within the previous year. This rate appears to be lower than that in the general population (approximately 80 percent), 55 underscoring the need for further investigation of the patterns of health care use among longterm survivors of acute lymphoblastic leukemia. We are indebted to Deqing Pei and Shelly Lensing for statistical analysis, Dr. James Boyett for statistical consultation, John Gilbert for assistance with scientific editing, Dr. Sarah Scholle for assistance with the insurance survey, Annette Stone and Margie Zacher for data management, Julie Groff for assistance with the figures, Kimberly Gayden for assistance in the preparation of the manuscript, many physicians (especially Drs. Rhomes J. Aur, H. Omar Hustu, Donald Pinkel, and Joseph V. Simone) for their contributions to the design and conduct of early Total Therapy studies, and the many patients and parents who participated in the research program.
* Students were not included in the employment analysis; some questions were not answered by all participants. CI denotes confidence interval.
National averages were calculated with adjustment for age and sex. † The national average was not within the 95 percent confidence interval. 
